Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharma entities : Viatris inc. save search
Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution)
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.0%
H: 1.03%
C: -1.34%
OCUP | $1.675 -3.74% -3.88% 240K
|
Health Technology
|
| O: 0.75%
H: 3.46%
C: -6.67%
fda pharma approval ryzumvl
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
Published: 2023-09-27 (Crawled : 12:00) - globenewswire.com
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.0%
H: 1.03%
C: -1.34%
OCUP | $1.675 -3.74% -3.88% 240K
|
Health Technology
|
| O: 0.75%
H: 3.46%
C: -6.67%
fda pharma approval treatment eye ryzumvl
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
Published: 2023-08-07 (Crawled : 12:00) - biospace.com/
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 2.46%
H: 5.81%
C: 1.38%
fda pharma drug sclerosis treatment application
Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting
Published: 2023-04-24 (Crawled : 12:00) - biospace.com/
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -1.35%
H: 0.11%
C: -2.0%
pharma sclerosis research meeting results
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
Published: 2023-03-30 (Crawled : 16:00) - biospace.com/
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.94%
H: 0.52%
C: -0.62%
OCUP | $1.675 -3.74% -3.88% 240K
|
Health Technology
|
| O: 0.83%
H: 5.51%
C: 5.51%
pharma year update financial results
Global Psoriasis Therapeutics Market Report to 2031 - Featuring Abbvie, Amgen, Bausch Health, LEO Pharma and Novan Among Others
Published: 2023-01-25 (Crawled : 21:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.69%
H: 0.87%
C: 0.69%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.97%
H: 0.11%
C: -1.25%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.36%
H: 0.34%
C: -0.85%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 1.91%
H: 3.28%
C: -0.23%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.09%
H: 0.53%
C: -0.35%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.0%
H: 0.06%
C: -0.65%
leo pharma global report therapeutics psoriasis market
Outlook on the Pharmaceutical Drugs Global Market to 2027: Look at the Changing Structure of the Pharma and Healthcare Industry
Published: 2023-01-03 (Crawled : 13:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 620K
|
n/a
|
| O: -1.13%
H: 28.57%
C: 19.0%
CSLLY | $87.96 3.3% 45K
|
n/a
|
| O: -3.93%
H: 2.17%
C: 1.75%
MNK | $0.3402 -0.06% 540K
|
n/a
|
| O: 3.1%
H: 0.0%
C: -2.75%
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.2%
H: 2.06%
C: 2.06%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.09%
H: 0.54%
C: 0.54%
UCBJY | $64.07 -4.38% 72K
|
Manufacturing
|
| O: 1.0%
H: 0.0%
C: -0.26%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 3.43%
H: 0.0%
C: -2.93%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.54%
H: 2.5%
C: 1.7%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 1.43%
H: 0.84%
C: -0.23%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.42%
H: 1.35%
C: 1.22%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.28%
H: 1.26%
C: 1.15%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.57%
H: 1.35%
C: 1.0%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 0.48%
H: 3.96%
C: -0.48%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.27%
H: 0.6%
C: 0.21%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.67%
H: 0.66%
C: 0.3%
pharma global market
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
Published: 2022-12-06 (Crawled : 15:00) - biospace.com/
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.18%
H: 0.92%
C: 0.28%
OCUP | $1.675 -3.74% -3.88% 240K
|
Health Technology
|
| O: 0.93%
H: 4.0%
C: -6.15%
nyxol fda pharma drug eye application submission
Mapi Pharma to Host a Key Opinion Leader Webinar on Glatiramer Acetate Depot
Published: 2022-10-12 (Crawled : 15:00) - biospace.com/
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.11%
H: 2.98%
C: -0.11%
pharma
Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)
Published: 2022-09-21 (Crawled : 13:00) - biospace.com/
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 1.66%
H: 2.88%
C: -1.63%
pharma trial positive sclerosis multiple sclerosis
Interstitial Cystitis Drugs Market - 36% of Growth to Originate from North America| Evolving Opportunities with Astellas Pharma Inc. & Bayer AG | 17000+ Technavio Reports
Published: 2022-06-01 (Crawled : 07:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 1.7%
H: 0.37%
C: -0.31%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 1.23%
H: 0.36%
C: -2.11%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
pharma growth market
Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive Multiple Sclerosis with a Sustained Release Glatiramer Acetate Depot
Published: 2022-03-30 (Crawled : 16:00) - biospace.com/
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.63%
H: 1.71%
C: -1.08%
pharma patent sclerosis multiple sclerosis
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.